

# Trends in Modern Drug Discovery

Jörg Eder and Paul L. Herrling

## Contents

1	The Beginnings of Modern Drug Discovery .....	4
1.1	Aspirin .....	5
1.2	Ergotamine .....	6
1.3	Penicillin .....	6
1.4	Steroid Hormones .....	7
2	Where Do Chemical Lead Structures Come from Today? .....	8
2.1	Origin of Libraries .....	8
2.2	HTS .....	10
2.3	FBS .....	10
2.4	Rational Drug Design .....	11
2.5	Target Family Knowledge .....	11
2.6	In Silico Methods .....	11
2.7	Biologics .....	12
3	Where Do Targets Come from? .....	12
4	Changing Landscape of Academic and Pharmaceutical Research .....	14
4.1	Laboratory Size .....	14
4.2	Research Center Size and Distribution .....	16
4.3	In-House and Outsourced Research, Academic Collaborations, and Consortia .....	17
4.4	Me-Too Drugs vs. Medical Breakthrough .....	18
4.5	Science Expertise and Culture at the Top .....	19
4.6	Productivity .....	19
	References .....	20

# Functional Genomics in Pharmaceutical Drug Discovery

Robert Adams, Michael Steckel, and Barbara Nicke

## Contents

1	Introduction .....	26
2	Types of RNAi Used in Screens .....	27
3	RNAi Screening Technologies .....	30
3.1	Synthetic Lethality .....	33
3.2	Assay Performance, Hit Identification, and Statistics in Plate-Based Screening .....	34
4	Addressing Off-Target Effects in RNAi Screens .....	34
5	CRISPR/Cas9 Target Screening .....	36
6	Conclusion .....	38
	References .....	39

# Emerging Target Families: Intractable Targets

Stefan Knapp

## Contents

1	The Concept of Druggability and Properties of Drug-Like Molecules .....	44
2	Example 1: Phosphatases, Classical Enzyme Targets with Low Druggability .....	46
3	Example 2: GTPases of the RAS Family .....	48
4	Example 3: Protein–Protein Interactions .....	50
	References .....	54

# In Vivo Target Validation Using Biological Molecules in Drug Development

Derek S. Sim and Katalin Kauser

## Contents

1	Ideal Animal Disease Model for Target Validation .....	60
2	In Vivo Models for Target Validation .....	60
2.1	Mammalian Models .....	60
2.2	Nonmammalian Models .....	63
3	Biological Tools for Target Validation .....	64
3.1	Biologic Approaches .....	64
3.2	Genetic Approaches .....	65
4	Challenges in Target Validation and Clinical Translatability of Preclinical Model .....	66
4.1	Translatability of Preclinical Animal Models: Hemophilia Mice as Examples .....	66
5	Conclusion .....	67
	References .....	67

# High-Throughput Synthesis of Diverse Compound Collections for Lead Discovery and Optimization

C. Rademacher and P.H. Seeberger

## Contents

1	Introduction .....	74
2	Principles of High-Throughput Synthesis in Lead Generation and Optimization .....	76
3	Combinatorial Peptide Synthesis .....	77
4	Automated Carbohydrate Synthesis .....	80
5	Biology-Oriented Synthesis .....	82
6	Diversity-Oriented Synthesis .....	84
7	Target-Oriented Synthesis and Lead Optimization .....	86
8	Conclusion .....	86
	References .....	87

# Sources for Leads: Natural Products and Libraries

Eric F. van Herwerden and Roderich D. Süßmuth

## Contents

1	Introduction .....	92
2	Natural Products .....	93
2.1	Recent Examples of Natural Products in Drug Discovery .....	94
2.2	Unexplored Sources of Natural Products .....	103
3	Chemical Libraries and Privileged Structures .....	107
3.1	Combinatorial Chemistry .....	107
3.2	Fragment-Based Drug Discovery (FDBB) .....	109
3.3	Diversity-Oriented Synthesis (DOS) .....	111
3.4	Privileged Structures .....	113
4	Conclusion .....	116
	References .....	118

# New Compound Classes: Protein–Protein Interactions

C. Ottmann

## Contents

1	Protein–Protein Interactions in Health and Disease .....	126
2	Physiological Regulation of PPIs .....	127
3	Small-Molecule Modulation of PPIs: Inhibition .....	127
4	Small-Molecule Stabilizers of PPIs .....	132
5	Conclusions and Outlook .....	133
	References .....	135

# Using Cheminformatics in Drug Discovery

Michael S. Lawless, Marvin Waldman, Robert Fraczkiwicz,  
and Robert D. Clark

## Contents

1	Introduction .....	140
2	Proof-of-Concept Target Selection .....	141
3	Design Strategy .....	142
4	Computational Methods .....	143
4.1	Data Set .....	143
4.2	Extracting Data from ChEMBL .....	143
5	Activity Cliff Detection and Matched Molecular Pair Analysis .....	145
6	Building Classification and Regression Models .....	148
7	Combinatorial Elaboration and Fragment Assembly .....	150
8	Virtual Library Creation by Combinatorial Enumeration .....	152
9	ADMET Risk™ .....	152
10	Physicochemical and Biological Characterization .....	154
10.1	COX-1 and COX-2 Assays .....	154
10.2	Thermodynamic Aqueous Solubility Assay .....	154
10.3	Stability in Human Liver Microsomes .....	154
10.4	LogD Measurements .....	155
11	Analysis and Modeling Results .....	155
11.1	Molecular Pair Analyses .....	155
11.2	QSAR Model Generation .....	157
12	Scaffold Hopping .....	159
13	Combinatorial Library Generation .....	162
14	Candidate Selection .....	162
15	How Good Were Our Predictions? .....	165
16	Conclusion .....	167
	References .....	167



# Implementation and Use of State-of-the-Art, Cell-Based In Vitro Assays

Gernot Langer

## Contents

1	Starting with a Short Historical Perspective .....	172
2	Scaling Down to Optimally Implement Robust and Reliable Test Systems .....	173
3	Working with Cells in a Miniaturised Format .....	175
4	Routine Cell Culture .....	175
5	Cells as Reagents (Frozen Cells) .....	176
6	Assay Culture Conditions .....	178
7	Cell-Based Assay Development .....	179
8	High Content Analysis: Getting the complete picture .....	185
	References .....	188

# **Translational In Vivo Models for Women’s Health: The Nonhuman Primate Endometrium—A Predictive Model for Assessing Steroid Receptor Modulators**

Ov Daniel Slayden

## **Contents**

1	Introduction .....	192
2	Use of Artificial Cycles .....	193
3	Induction of Menstruation .....	193
4	Steroid Receptor Antagonists .....	194
5	Induction of Endometriosis .....	197
6	Conclusions .....	197
	References .....	198

# Predictive In Vivo Models for Oncology

Diana Behrens, Jana Rolff, and Jens Hoffmann

## Contents

1	Introduction .....	204
2	Demands on Target Identification and Validation Models .....	204
3	Tumor Models in the Lead Identification and Optimization (LO) Process .....	207
4	Translational Research (TR) Process .....	208
5	Mouse and Rat Strains for Preclinical Oncology Research .....	209
6	Humanized Mice .....	211
7	Scopes of Patient-Derived Xenografts .....	211
8	Translational Preclinical Studies with PDX Can Identify Predictive Response Marker	213
9	Current Limitations .....	214
10	Outlook .....	215
	References .....	216

# Translational In Vivo Models for Cardiovascular Diseases

Daniela Fliegner, Christoph Gerdes, Jörg Meding,  
and Johannes-Peter Stasch

## Contents

1	Introduction .....	224
2	Animal Models in Cardiovascular Diseases: The Demands on Target Identification, Validation Models, and the Translation .....	225
2.1	Heart Failure .....	225
2.2	HF Induced by Myocardial Infarction .....	225
2.3	HF Induced by DOCA .....	226
2.4	Pulmonary Hypertension .....	227
2.5	Thrombotic Diseases .....	230
2.6	Animal Models for Anticoagulation Testing .....	230
3	Conclusion and Limitations .....	232
	References .....	232

# Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug Efficacy and Safety

Andreas Reichel and Philip Lienau

## Contents

1	Introduction .....	236
2	Pharmacokinetics in Drug Discovery .....	239
	2.1 Target Validation .....	239
	2.2 Lead Generation .....	240
	2.3 Lead Optimisation .....	243
	2.4 Candidate Selection and Profiling .....	249
3	Summary and Outlook .....	255
	References .....	257

# Nonclinical Safety and Toxicology

Claudia Stark and Thomas Steger-Hartmann

## Contents

1	Introduction .....	262
2	Molecular Off-Target Interaction .....	264
3	Genotoxicity .....	265
4	General Toxicity .....	266
5	Cardiovascular Effects and Cardiotoxicity .....	268
6	Central Nervous Effects and Neurotoxicity .....	269
7	Hepatotoxicity .....	270
8	Renal Function and Nephrotoxicity .....	272
9	Respiratory Function and Pulmonary Toxicity .....	272
10	Developmental Toxicity .....	273
11	Carcinogenicity .....	274
12	Other Nonclinical Safety Aspects .....	274
	12.1 Phototoxicity .....	274
	12.2 Phospholipidosis .....	275
	12.3 Mitochondrial Toxicity .....	276
	12.4 Immunotoxicity .....	276
13	Omics Technologies .....	277
14	Exploratory Clinical Screening .....	278
15	Accessing and Assessing the Acquired Screening Data .....	278
	References .....	279

# Impact of Biomarkers on Personalized Medicine

Patricia Carrigan and Thomas Krahn

## Contents

1	Introduction .....	288
2	Biomarker Classification .....	290
2.1	Does This New Drug Hit the Planned Target? .....	290
2.2	Is This Drug Safe? .....	290
2.3	Is the Therapy More Effective in One Population? .....	291
2.4	Does the Biomarker Predict Survival? .....	291
2.5	Is This Biomarker Unique to Disease Status? .....	292
2.6	Does This Biomarker Guide Treatment Decisions? .....	292
3	Biomarker Technologies .....	292
3.1	Technology Trends and Applications .....	292
3.2	Technologies Based on the Molecular Basis of Biomarker .....	293
3.3	DNA Biomarkers .....	294
3.4	RNA Biomarkers .....	295
3.5	microRNA .....	295
3.6	lncRNA .....	296
3.7	Epigenetic Factors .....	297
3.8	Protein Biomarker .....	297
3.9	Immunoassays: Direct Use of Antibodies .....	298
3.10	Mass Spectrometry Assays .....	298
3.11	Autoantibodies .....	299
3.12	Exosomes, Microvesicles .....	299
3.13	Rare Cells, Immune Cells .....	300
4	De-risking Drug Development .....	300
5	Biomarkers and Companion Diagnostics .....	302
5.1	Biomarkers: Laboratory Developed Test or Companion Diagnostic .....	304
5.2	Laboratory Developed Test and Companion Diagnostic Requirements .....	305
5.3	Regulatory Authorities .....	307

# Modeling and Simulation of In Vivo Drug Effects

Jörg Lippert, Rolf Burghaus, Lars Kuepfer, Bart Ploeger,  
Stephan Schaller, Walter Schmitt, and Stefan Willmann

## Contents

1	Introduction .....	314
2	Modeling and Simulation Approaches .....	316
3	Representation of Biological and Pharmacological Complexity .....	319
4	Applications of Modeling and Simulation to Situations with Limited Mechanistic Understanding .....	323
5	Conclusions .....	327
	References .....	327